Compare Neurocrine Biosciences Inc (NBIX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Recursion Pharmaceuticals Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Neurocrine Biosciences Inc is far larger — about 11.4× Recursion Pharmaceuticals Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | RXRX | |
|---|---|---|
Market Cap | $17.40B | $1.53B |
Sector | Health | Health |
52-Week High | $180.55 | $6.79 |
52-Week Low | $123.10 | $2.84 |
Enterprise Value | $16.49B | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
